Identification of Early Markers of Alzheimer's Disease by Using Eye Tracking in Reading.
NCT ID: NCT02557464
Last Updated: 2023-11-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
14 participants
INTERVENTIONAL
2015-11-10
2018-07-05
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Long-term Follow-up of Patients Included in the EYE-TAR(MA) Study.
NCT05254873
Autobiographical Memory
NCT04584138
Spatial and Ocular Trajectories for the Early Diagnosis of Alzheimer's Disease.
NCT06213766
Ecological Assessment of Apathy in Alzheimer's Disease and in Control Subjects: Video Recognition and Actigraphy
NCT01384344
Rehabilitation of Facial Emotion Recognition in Alzheimer's Disease
NCT05267028
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Identifying Alzheimer's disease (AD) as early as possible should enable to propose a re-education platform that would fit the early stage of neuronal loss in this pathology. Neuropsychological evaluations are currently one of the main tools for the early screening of AD. Among the tests proposed during those evaluations, the investigator find the Isaacs Set Test which evaluates the early degradation of semantic memory. Whereas eyes movement behavior during reading is sensitive to semantics factors and allows collecting accurate measurements (as precisely as one millisecond), no study has yet used this technique to precisely identify the precocious semantics troubles of AD.
Goal:
The objective of this study is to identify early and accurate markers of AD by associating semantic neuropsychological assessments and eye tracking during sentences reading.
Method:
The study will include 24 patients with AD or related disorders (Mini Mental State Examination between 20 and 27 ) and 24 age matched controls participants. The experiment will be divided in two steps. First, patients will take a standard neuropsychological evaluation. A specific semantic analysis will be performed on each participant using, for example, the Isaacs Set Test or the Weschler Similarities. The second step will ask the participants to read sentences while an eye tracker (the Eye Link 1000 remote) will record their eyes movements. In order to manipulate semantics factors, each sentence will contain a target word, either predictable or not. The experiment will last one hour and a half. Neuropsychological assessments and eye tracking will be done twice with a time interval of 6 months. The two times will be called T1 and T2 and are required to estimate whether eye tracking is a better predictor of AD than neuropsychological tests or not.
Evaluation criteria:
The eye tracking technique enables to record different sorts of measures. More specifically, the investigator will evaluate gaze duration on the target word. Moreover, neuropsychological tests scores will be collected. It will be, for example, the number of good answers.
Hypothesis and expected results:
First, the investigator expect that the predictability effect on eye movements would be less pronounced for patients with AD or related disorders than for the control group. This effect would be even more diminished at T2. It could be explained by a progressive degradation of the semantic memory of patients. Then, and for the same reasons, the investigator expect that the scores collected from the neuropsychological tests would be pathological for patient suffering from AD or related disorders. The test scores would be even more in deficit at T2. Finally, the investigator predict a correlation between neuropsychological tests data and eye movements data. With an extrapolation, and because eye movements recording allow us to obtain more accurate information about the quality of semantic processes, the investigator formulate the hypothesis that this technique will help to predict earlier AD.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Alzheimer's disease group
24 patients with an Alzheimer's disease or related disorders
An eye tracking experiment
Neuropsychological assessments and eye tracking during reading will be practice twice with an interval of 6 months
A neuropsychological evaluation
Neuropsychological assessments and eye tracking during reading will be practice twice with an interval of 6 months
control group
24 age matched controls participants
An eye tracking experiment
Neuropsychological assessments and eye tracking during reading will be practice twice with an interval of 6 months
A neuropsychological evaluation
Neuropsychological assessments and eye tracking during reading will be practice twice with an interval of 6 months
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
An eye tracking experiment
Neuropsychological assessments and eye tracking during reading will be practice twice with an interval of 6 months
A neuropsychological evaluation
Neuropsychological assessments and eye tracking during reading will be practice twice with an interval of 6 months
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Mother tongue french participants
* Participants with a level of education = or \> to Junior Secondary School Diploma
* Participants with a normal or corrected vision
* Participants with good score at the neuro visual assessments (\> or = to 15 at the "detection test" ; \> or = to 16 at the "degraded letters" test
* Participants suffering from Alzheimer's or related disorders disease (ICD-10 criteria)
* Participants with an MMSE's score between 20 and 27
* Participants must sign the informed consent
* Impossibility to realize the experiment because of a blurred vision
* History of neurological or psychiatric disease, of alcoholism and of brain injury
* Participants under trusteeship, guardianship or placed under judicial protection
* Persons deprived of their liberty
Pour le bras B :
* Mother tongue french participants
* Participants with a level of education = or \> to Junior Secondary School Diploma
* Participants with a normal or corrected vision
* Participants with no global cognitive impairment with a MMSE's score \> or = to 28 and with no difficulty to repeat and recall the 3 words
* Participants with good score at the neuro visual assessments (\> or = to 15 at the "detection test" ; \> or = to 16 at the "degraded letters" test
* Participants must sign the informed consent
* Impossibility to realize the experiment because of a blurred vision
* Prescription of psychotropic medication during the week preceding the experiment
* History of neurological or psychiatric disease, of alcoholism and of brain injury
* Evidence of cognitive decline
* Decline in the day-to-day operations
* Participants under trusteeship, guardianship or placed under judicial protection
* Persons deprived of their liberty
60 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Centre Hospitalier Universitaire de Nice
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Institut Claude Pompidou
Nice, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
15-AOI-04
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.